New data suggest a link between usingGLP-1receptoragonists(GLP-1RAs) and a significantly higher risk fortendonruptures, primarily tears involving the rotator cuff, Achilles, and pectoralis ...
Scope of Problem and Purpose Glucagon-like peptide-1receptoragonists(GLP-1RAs) have revolutionized the care of patients with metabolic disease due in part to theagonists'unique combination of effects, including decreasing hyperglyce-mia and enhancement of satiety.1,2GLP-1, a naturally secreted polypeptide, acts on theGLP-1R in multiple organs, including the pancreas, brain, heart ...
Glucagon-like peptide1(GLP1)agonistsforadults with Type 2 Diabetes (T2DM) BackgroundGLP-1agonistsbind to and activateGLP-1receptorsto stimulate insulin secretion, lowering glucagon secretion when blood glucose is high, and delaying gastric emptying in the early post-prandial phase.
This suggestion is irrespective of the indication (type 2 diabetes mellitus or weight loss), dose, or the type of procedure/surgery. IfGLP-1agonistsprescribed for diabetes management are held for longer than thedosingschedule, consider consulting an endocrinologist for bridging the antidiabetic therapy to avoid hyperglycemia.
American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients on Glucagon-Like Peptide-1 (GLP-1)ReceptorAgonistsGlucagon-like peptide-1 (GLP-1)receptoragonistsare approved by the Food and Drug Administration for treatment of type 2 diabetes mellitus and cardiovascular risk reduction in this cohort.
There is a need for local evidence-basedguidelinesto best manage patients onGLP-1RAs and dualGLP-1and glucose-dependent insulinotropic polypeptidereceptorco-agonists(GLP-1/GIPRAs) presenting for surgical and medical procedures requiring sedation or anaesthesia.
